Switch to
View more

Supriya Lifescience Ltd

SUPRIYA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,816 cr, stock is ranked 652
High RiskStock is 3.64x as volatile as Nifty
349.905.85 (-1.64%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,816 cr, stock is ranked 652
High RiskStock is 3.64x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
18.55
PB RatioPB Ratio
10.48
Dividend YieldDiv. Yield
0.16%
Sector PESector PE
34.89
Sector PBSector PB
4.47
Sector Div YldSctr Div Yld
0.90%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Supriya Lifescience is a manufacturer of pharmaceutical preparation.

Investor PresentationView older 

Jul 8, 2022

PDF
View Older Presentations

Financial TrendFinancial statements 

2019202020212022285.86322.71396.23537.6339.4273.36123.61151.80
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Schedule of Analysts/Institutional Investor Meet/Con. Call 
Announced OnAug 6, 2022

Supriya Lifescience Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call will be held on Tuesday, August 16, 2022 at 3.00 P.M. IST to discuss operational and financial performance of the Company for the quarter ended June 30, 2022 (Q1 of FY 2022-23). The invite giving requisite details including the pre-registration link and dial-in details is attached herewith.This intimation is also being made available on the website of the Company at:https://supriyalifescience.com/investor-relation/ Kindly take the information on record. | Download

Supriya Lifescience Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call will be held on Tuesday, August 16, 2022 at 3.00 P.M. IST to discuss operational and financial performance of the Company for the quarter ended June 30, 2022 (Q1 of FY 2022-23). The invite giving requisite details including the pre-registration link and dial-in details is attached herewith.This intimation is also being made available on the website of the Company at:https://supriyalifescience.com/investor-relation/ Kindly take the information on record. | Download

General updates 
Announced OnJul 8, 2022

Supriya Lifescience Limited has informed the Exchange about Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2022 | Download

Supriya Lifescience Limited has informed the Exchange about Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2022 | Download

Investor Presentation 
Announced OnJul 8, 2022

Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited (¬タワCompany¬タン) will be interacting with Analyst/Institutional Investors on July 8, 2022 via video conference.This is to further inform that the copy of the Investor Presentation has been uploaded on the Stock Exchanges and on the Company¬タルs website www.supriyalifescience.com for your information and for the information of your members and the public at large.This information is submitted to you pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.Note: The above date is subject to change. Change may happen due to exigencies on the part of Company or Analyst/Investor/Fund.Request you to kindly take the same on record. | Download

Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited (¬タワCompany¬タン) will be interacting with Analyst/Institutional Investors on July 8, 2022 via video conference.This is to further inform that the copy of the Investor Presentation has been uploaded on the Stock Exchanges and on the Company¬タルs website www.supriyalifescience.com for your information and for the information of your members and the public at large.This information is submitted to you pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.Note: The above date is subject to change. Change may happen due to exigencies on the part of Company or Analyst/Investor/Fund.Request you to kindly take the same on record. | Download

See all events